| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DOM.12854 |
| P698 | PubMed publication ID | 27987248 |
| P50 | author | Fabrice Bonnet | Q51498468 |
| André Scheen | Q89002159 | ||
| P2093 | author name string | André Scheen | |
| P2860 | cites work | Clinical Pharmacokinetics of Metformin | Q22241422 |
| Molecular mechanism of action of metformin: old or new insights? | Q22252798 | ||
| Sulphonylurea monotherapy for patients with type 2 diabetes mellitus | Q24197884 | ||
| New mechanisms of metformin action: Focusing on mitochondria and the gut | Q26778766 | ||
| Cellular and molecular mechanisms of metformin: an overview | Q27013561 | ||
| SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis | Q28076978 | ||
| Metformin and the gastrointestinal tract | Q28079250 | ||
| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis | Q28240230 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Importance of the intestine as a site of metformin-stimulated glucose utilization | Q30498794 | ||
| Clinical outcomes and adherence to medications measured by claims data in patients with diabetes | Q30977056 | ||
| Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. | Q33838229 | ||
| Effect of metformin on metabolic improvement and gut microbiota | Q34261321 | ||
| How do patients' treatment preferences compare with those of clinicians? | Q34354202 | ||
| Metformin as a cause of late-onset chronic diarrhea | Q34443375 | ||
| Metformin kinetics in healthy subjects and in patients with diabetes mellitus | Q34449285 | ||
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
| Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis | Q34522524 | ||
| Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis | Q34534590 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study | Q34644993 | ||
| Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). | Q34661985 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report | Q34727990 | ||
| An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice | Q34785134 | ||
| Effect of gastric bypass surgery on the absorption and bioavailability of metformin. | Q35043256 | ||
| Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels | Q35584944 | ||
| Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. | Q35675566 | ||
| Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study | Q35761408 | ||
| Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial | Q35794567 | ||
| Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota | Q35860108 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Metformin: an old but still the best treatment for type 2 diabetes | Q36715464 | ||
| Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials | Q37059366 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Health information, behavior change, and decision support for patients with type 2 diabetes: development of a tailored, preference-sensitive health communication application | Q37254902 | ||
| Impact on glycated haemoglobin of a biological response-based measure of medication adherence | Q37275626 | ||
| Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes | Q37340297 | ||
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated | Q37509313 | ||
| Metformin effects revisited | Q37554697 | ||
| DPP-4 inhibitors: what may be the clinical differentiators? | Q37779906 | ||
| Advantages of extended-release metformin in patients with type 2 diabetes mellitus | Q37835611 | ||
| DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials | Q37971194 | ||
| Fixed-dose combinations for treatment of type 2 diabetes mellitus | Q37978206 | ||
| Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy | Q37982231 | ||
| Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study | Q38044043 | ||
| Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis | Q38105641 | ||
| A review of gliptins for 2014. | Q38266290 | ||
| Metformin: from mechanisms of action to therapies | Q38279824 | ||
| Combination therapy when metformin is not an option for type 2 diabetes | Q38377267 | ||
| Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone | Q38494899 | ||
| Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review | Q38563239 | ||
| Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. | Q38855893 | ||
| The "slower" the better. | Q39107512 | ||
| Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy | Q40758301 | ||
| Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients | Q40869186 | ||
| Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes | Q40880873 | ||
| Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis | Q40922432 | ||
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. | Q41000321 | ||
| Clinical pharmacokinetics of metformin | Q41066472 | ||
| Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus | Q41665921 | ||
| Oral antidiabetic agents. A guide to selection | Q41722668 | ||
| Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes | Q43142540 | ||
| What is the phenotype of patients with gastrointestinal intolerance to metformin? | Q43543490 | ||
| Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial | Q43809926 | ||
| Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect | Q44068560 | ||
| Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, pla | Q45218148 | ||
| Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study | Q45389552 | ||
| Metformin and the intestine | Q46557959 | ||
| Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial | Q46595958 | ||
| Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study | Q46773983 | ||
| Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database | Q46783489 | ||
| Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. | Q50876480 | ||
| Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) | Q51281907 | ||
| Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. | Q51350925 | ||
| The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. | Q51376983 | ||
| Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. | Q51501042 | ||
| Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. | Q51566458 | ||
| Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. | Q51568639 | ||
| Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. | Q51572280 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
| Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. | Q51644543 | ||
| Increased F-18 FDG Intestinal Uptake in Diabetic Patients on Metformin | Q57711670 | ||
| P433 | issue | 4 | |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 473-481 | |
| P577 | publication date | 2017-02-22 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Understanding and overcoming metformin gastrointestinal intolerance | |
| P478 | volume | 19 |
| Q64063960 | Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study |
| Q92593539 | Based on network pharmacology to explore the molecular mechanisms of astragalus membranaceus for treating T2 diabetes mellitus |
| Q64916595 | Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. |
| Q99565462 | Fermentation of Danggui Buxue Tang, an ancient Chinese herbal mixture, together with Lactobacillus plantarum enhances the anti-diabetic functions of herbal product |
| Q38629338 | Hydration status, drug interactions, and determinants in a Spanish elderly population: a pilot study |
| Q94502600 | Lycium barbarum Polysaccharides Improve Testicular Spermatogenic Function in Streptozotocin-Induced Diabetic Rats |
| Q98200280 | Metformin and COVID-19: From cellular mechanisms to reduced mortality |
| Q90140024 | Metformin in 2019 |
| Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
| Q49991307 | Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin |
| Q59796915 | Scutellariae Radix and Coptidis Rhizoma Improve Glucose and Lipid Metabolism in T2DM Rats via Regulation of the Metabolic Profiling and MAPK/PI3K/Akt Signaling Pathway |
| Q41999356 | Severity of Gastrointestinal Side Effects of Metformin Tablet Compared to Metformin Capsule in Type 2 Diabetes Mellitus Patients |
| Q89670151 | Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study |
| Q89869494 | The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients |
| Q64075988 | Treatment Shows Protective Effects on Renal Injury and Metabolic Modulation in db/db Mice |
| Q92797743 | Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus |
Search more.